Compare abrdn Income Credit Strategies Fund (ACP) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs DENTSPLY SIRONA Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while DENTSPLY SIRONA Inc trades at $11.77 (market cap $2.44B). The key difference: DENTSPLY SIRONA Inc is far larger — about 3.7× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | XRAY | |
|---|---|---|
Market Cap | $656.21M | $2.44B |
Sector | Financials | Health |
52-Week High | $5.98 | $16.85 |
52-Week Low | $5.01 | $9.64 |
Dividend Yield | 17.78% | 5.04% |
Enterprise Value | — | $4.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
XRAY trades at $12.19, up 4.64% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $0.27, missing estimates of $0.28, continuing a trend of earnings misses. Revenue declined to $3.68B in 2025 with a net loss of $598M, though gross margin remains healthy at 48.93%. Recent news highlights distribution expansions and AI-enabled product launches, supporting growth initiatives amid ongoing profitability challenges.
The outlook remains mixed: analyst consensus is a 'Hold' with a $12.50 price target, near current levels. Upside potential exists from digital dentistry adoption and cost controls, but risks include persistent net losses, high debt-to-asset ratio of 42.88%, and competitive pressures. Investors should weigh stabilization efforts against margin headwinds and macroeconomic softness in European markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
